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ABSTRACT 
Objective: Circulating autoantibodies have been extensively investigated as possible markers for early diagnosis of cancer. The present study was 
carried out to investigate whether anti-HABPs autoantibodies could be classified as a serum biomarker for malignant tumors.  
Methods: An enzyme-linked immunosorbent assay, western blot was used to detect anti-HABPs autoantibodies in sera from 99 patients with 
various types of cancers and 50 healthy subjects matched by age and gender.  
Result: Our results clearly indicated that patients with cancer have significant higher circulating levels of anti-HABPs antibodies as compared to 
control subjects (� < 0.001). Receiver operating characteristic plot test has exhibited 91.9% sensitivity and 76.3% specificity.  
Conclusion: anti-HABPs autoantibodies are promising biomarker for malignant tumors and could play a role in the development of multimarker 
assay for the early detection of cancer. 
Abbreviations: HABPs, hyaluronic acid binding proteins; ELISA, enzyme linked immune sorbent assay; AAbs, autoantibodies; BSA, bovine serum 
albumin; HA, hyaluronic acid; bHA, biotinlyted hyaluronic acid; ROC, receiver operating characteristics; AUC, area under curve; TAA, tumor 
associated antigen; ABTS, 2,2'azino bis (3ethylbenzothiazoline 6 sulphonic acid); MES buffer, 2 (N morpholino) ethanesulfonic acid; EDC,1 Ethyl 3 (3 
dimethylamino propyl) carbodiimide; DMSO, dimethyl sulfoxide; PVDF, polyvinylidene fluoride; ECL, enhanced chemiluminescence 
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INTRODUCTION 
Early detection and diagnosis are of utmost importance in cancer 
management. Despite significant improvements in treatment, early 
detection remains the most important prognostic factor prediction 
[1,2] Current cancer screening methods, including colonoscopy for 
colon cancer [3], computed tomography for lung cancer, 
papanicolaou stains for cervical cancer, mammography of better 
outcome for breast cancer, PSA for prostate cancer and have 
demonstrated some limitations in terms of sensitivity, specificity 
and complexity [4]. Serum tumor associated antigens (TAA) have 
been extensively studied for early cancer detection because of 
simplicity and reliability of test used for their determination, such as 
western blot and enzyme-linked immunesorbent assay (ELISA). 
Unfortunately, they are transiently secreted and rapidly eliminated 
from blood circulation [5] and usually reach a detectable 
concentration only in the advanced stage of cancer [6].  
In conjunction with TAAs, autoantibodies are frequently detected in 
sera from patients affected by different types of tumors [7]. This 
finding has been interpreted as an attempt of the immune system to 
block invasion and spreading of cancer cells in the organism. 
Circulating autoantibodies have biochemical and biological 
characteristics that relinquish them particularly suitable to screen 
subjects at early risk of cancer. In a point of fact, they may develop 
early in the process of tumorigenesis, when premalignant or 
malignant cells inaugurate to express altered proteins as a result of 
cell transformation [8]. In addition, they can easily be detected in the 
serum because of the usual high concentration and long-time 
stability [7]. For these reasons, great efforts have been made in 
recent years to identify circulating autoantibodies directed against 
cancer-related proteins in order to build up tests for the early 




In present study, we investigated the production of autoantibodies 
against HABPs in patients affected by different types of cancer. 
These HABPs, also has been largely regarded as a TAA, since their 
present at elevated concentrations in the blood of cancer patients 
and is over expressed in the vast majority of cancer serum/tissues 
[10]. In fact, HA can bind important proteins associated with the 
membrane of tumor cells, such as H11, CD44, cdc37. [11]. HA-HABPs 
has also been implicated in cancer progression by modulating tumor 
cell adhesion, cell proliferation and invasion processes. Here we 
show that patients with different types of cancer, but not healthy 
controls, develop autoantibodies against HABPs. This finding 
discloses the capability of HABPs to trigger a humoral immune 
response in cancer patients and provides the basis for further 
investigation on a possible use of anti-HABPs antibodies as 
biomarkers for early diagnosis of cancer. 
PATIENTS WITH METHODS 
Subjects 
We tested 149 serum samples from patients with cancer (n= 99) and 
normal HC (n=50), ninety nine consecutive patients with early (N = 
40), (N = 37) and (N = 22). Related cancer includes (male 32 and 
female 67), HC (male 28 and female 22). All human samples were 
collected prospectively at Preethi center for oncology, Bharath 
cancer hospital and KR hospital. The cancers were various cell types 
breast (n = 20, mean age ± SEM = 50.6 ± 14.4 years), cervical (n = 23, 
mean age ± SEM = 47.2 ± 15.5 years), colon (n = 18, mean age ± SEM 
= 52.2 ± 12.2 years), ovary (n = 13, mean age ± SEM = 59.5 ± 15.1 
years), stomach (n = 12, mean age ± SEM = 56.5 ± 15.6 years), 
Rectum (n= 4, mean age ± SEM = 59.7 ± 9.3 years), lung (n =9,mean 
age ± SEM = 45.2 ± 15.5), healthy control (n = 50, mean ± SEM = 38.7  
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± 15.5 years), (shown in table 1). All the samples were handled and 
stored essentially with the same protocol. Written informed consent 
was obtained from each subject. The study protocol conformed to 
the Institutional Ethical Review Board–approved by University of 
Mysore  
Preparation of biotinylated hyaluronic acid probe 
500μg of the hyaluronic acid (across USA) was dissolved in 500μL of 
0.2 M MES buffer (pH 5.5). To this solution, 1mM biotin-LC-
hydrazide (dissolved in DMSO) and 10mM EDC were added. The 
reaction mixture was incubated at 4ºC for 16h. This was dialyzed 
against PBS pH 7.4 for 36h at 4ºC. Finally, the dialyzed bHA was 
stored in glycerol at –20ºC [12]. 
Detection of hyaluronic acid binding proteins by bHA polymer 
HABPs were detected by solid phase ELISA using Maxi Sorp flat-
bottom high protein-binding capacity polystyrene 96 well plates. 
The plates were coated with 100µl of diluted circulating cancer, 
other diseases (other than cancer) and healthy controls serum 
(5µg/mL concentration in 50mM carbonate/bicarbonate buffer pH 
9.6.) Each sample was coated in triplicate and half of the plate served 
as control, coated samples were incubated overnight at 4 0 C. Then 
plates were washed with washing buffer (50 mM Phosphate buffer, 
0.1% bovine serum albumin (BSA), 0.05% tween-20 pH 7.4. After 
washing, non specific binding sites were blocked with 100 µL of 5% 
inactivated serum, 5% non fat dry milk, 1% BSA, 0.05% Tween-20 
for 1 hr at room temperature and washed thrice with washing 
buffer. Then incubated with 100 µL of 1:1000 dilution bHA for 1 hr 
at 370C. After extensive washes again incubated with 100 µL of 
1:15,000 diluted goat anti-human biotin conjugate, for 1hr at room 
temperature, Finally the reaction was developed using 100 µL of 
ABTS substrate (1% ABTS 0.1 M citric acid 0.2 M Na2HPO4 and 30% 
H2O2).The reaction was stopped by adding 100 µL of 200 mM 
sodium citrate buffer and the absorbance was read at 450nm on an 
ELISA reader (micro plate reader Texan Magellan, Sweden). 
Absorbance was mentioned as mean ± SEM. 
Partial purification of hyaluronic acid binding proteins (HABPs) 
Pre-swollen QAE Sepharose (fast flow sigma) was packed onto a 
(1.5x15cm) column. The column was then equilibrated with 50mM 
Tris pH 8.0. 100mg (diluted to 1 mL) of cancer sera was loaded and 
was eluted with elution buffer containing different NaCl 
concentrations (50, 150, 220 & 300 mM). Fractions were read at 
280nm. Each peak was dialyzed and lyophilized.  
Affinity purification of HA-Binding proteins (Anders Tengblad, 
1979) 
Preparation of HA-Sepharose column: 100mg of hyaluronic acid was 
dissolved in 30ml of 0.05M sodium acetate containing 0.15M NaCl 
(pH 5.0). For complete dissolving of HA, keep it overnight. To the 
dissolved HA add 2mg of hyaluronidase and incubate the mixture at 
room temperature for 3hours and then boil it for 10min. Centrifuge 
at 10,000 rpm for 15min and take the supernatant. Take 10mL of 
EAH-Sepharose 4B and add the digested HA solution and 250mg of 
EDC to it. Keep the mixture in a stirrer and mix it for 6hr keeping pH 
constant at 5.0. Adjust the pH with 0.1M HCl. After 6 h add 2mL of 
glacial acetic acid and incubate for 6hr. Later wash the gel with 1M 
NaCl and then with 0.05M formate buffer pH 3.0. Wash with distilled 
water and store the mixture at 4oC. Equiliberate the HA-Sepharose 
column with 4.0M guanidium HCl containing 0.5M sodium acetate 
pH 5.0. Load the 50,150mM Q-Sepharose fraction onto the column. 
Re-circulate at least 3 times. Wash the column to remove the 
unbound fraction. Elute the protein with 4M guanidium HCl. [13-15] 
Detection of anti-HABPs autoantibody by ELISA 
Autoantibodies against HABPs were measured by solid phase ELISA 
using Maxi Sorp flat-bottom high protein-binding capacity 
polystyrene 96 well plates. The plates were coated with 100µl                    
of diluted circulating purified HABPs with 5µg/mL concentration in  
 
 
50mM    carbonate / bicarbonate  buffer  pH 9.6.  Each   sample   was 
coated in triplicate and half of the plate served as control of the 
purified human HABPs and were incubated overnight at room 
temperature. Then plates were washed with washing buffer (50 mM 
Phosphate buffer, 0.9% NaCl, 0.1% bovine serum albumin (BSA) of 
pH 7.4. After washing, the plates were blocked with 100 µL of 
blocking buffer (5% inactivated serum, 1% BSA, 0.05% Tween-20) 
for 1 hr at room temperature and washed thrice with washing 
buffer. Then incubated with 100 µL of 1000 fold diluted patient and 
control serum samples (dilution buffer: PBS pH 7.4, 0.25% BSA and 
0.05% Tween 20) for 1 hr at 370C. After three washes with washing 
buffer and again incubated with 100 µL of 15,000 fold diluted goat 
anti-human IgM horseradish peroxidase conjugate in PBS, 0.9% 
NaCl, and 1% BSA for 1hr at room temperature, followed by five 
times washes with washing buffer. Finally the reaction was 
developed using 100 µL of ABTS substrate (1% ABTS 0.1 M citric 
acid 0.2 M Na2HPO4 and 30% H2O2 ).The reaction was stopped by 
adding 100 µL of 200 mM sodium citrate buffer and the absorbance 
was read at 450 nm on an ELISA reader (micro plate reader Texan 
Magellan, Sweden). Absorbance was mentioned as mean ± SD. 
Immunoblot analysis  
The purified human circulatory HABPs (50 µg) were subjected to 
10% SDS-PAGE, under reducing conditions at constant voltage (100) 
and electro blotted onto PVDF membrane (Millipore USA) for 45 min 
at 50 volts, then membrane was blocked, (5% CaCl2 inactivated 
human serum, 1% BSA, 5% non fat dry milk) for 1 hr at room 
temperature and the membrane was washed with washing buffer 
(TTBS-Tris, NaCl and Tween-20 pH 8.0) and the blotted strips were 
incubated with 1:100 dilution cancer patients and HC sera in T-TBS 
for overnight at 40C. Next strips were incubated with bHA, mAb 
CD44, and cdc 37 antibody. The strips were washed and then 
incubated with secondary antibody (goat anti-human IgM-
horseradish peroxidase conjugate 10,000 fold dilutions) for 1 hr at 
room temperature and immune reaction was detected by ECL 
(enhanced chemiluminescence (Amersham Pharmacia). 
Statistical analysis  
The comparison of different cancer and HC result are expressed as 
mean ± SEM and were analyzed by the use of unpaired t-test, one 
way ANOVA test and the difference was consider statistically 
significant when p < 0.05. Multivariance analysis was based on 
receiver operating characteristics (ROC) curves, which allow the 
characterization of discrimination between two well defined groups. 
The receiver operating characteristic criterion [16,17] finds the 
immense linear and area under the curve ( AUC) is maximized. 
Sensitivity, which represents its ability to detect the diseased 
population and specificity, represents its ability to detect the non 
diseased population. Statistical analysis was done with the use of 
graphpad prism software 5.0 [18]. 
Results 
HABPs detection 
To detect HA-binding proteins we adapted a simple ELISA technique, 
biotinylated HA polymer reacted with HABPs in cancer when 
compared with HC and positive other diseases (p˂ 0.001), has 
shown (Fig.1a). 
HABPs purification 
HABPs were partially purified by strong anion exchanger Q 
Sepharose column, fractionated with increasing salt gradient and 
each pooled peak was tested for HABPs activity (Fig.1b) only in 
50,150mM fractions shown maximum reaction (Fig.1c), therefore we 
have pick out 50,150mM fractions and further affinity purified by 
EAH Sepharose column. Guanidinium HCl elutated fractions was run 
under reducing condition and transblotted reacted with bHA 
polymer, multiple HABPs (120 kD, 80 kD, 57 kD, 47 kD and 37 kD ) 
was shown with strong reaction (Fig.7 lane 4)  
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Figure.1a shows detection of HA-binding proteins by biotinylated 
bHA polymer, bHA binds to HABPs, HC as a negative control and 
other diseases as a positive control. There is a significant difference 
between HC vs cancer, cancer vs other diseases (p ˂0.001).1b. 
Elution profile of different NaCl concentrated (50 mM, 150,200,300 
and 500 mM)) strong anion exchange Q Sepharose column fractions. 
1c. Partially purified Q Sepharose fractions were screened for HA-
binding proteins by biotinylated HA polymer  
Anti-HABPs autoantibodies detection in the sera of patients 
with cancer:  
Serum anti-HABPs autoantibodies levels were significantly higher in 
patients with cancer (0.98 ± 0.51) compared to those with HC. 
(0.257 ± 0.22) (P value 0.001). HA-HABPs excretion or secretion 
might elicit the induction of serum autoantibodies. Let us to develop 
a novel ELISA method to measure the anti-HABPs autoantibody, sera 
obtained from 99 patients with cancer and 50 healthy subjects were 
investigated for the presence of anti-HABPs autoantibodies. The 
reactive proteins most commonly observed in patient with cancer 
sera but not significantly with HC.  
 
Fig.2 
Figure.2 shows titers of anti-HABPs autoantibody in sera of patient 
with different types of cancer and HC. Anti-HABPs autoantibody was 
measured by ELISA. Autoantibody titers were arbitrary expressed as 
a mean absorbance values = 0.257 (broken line) was considered as a 
positive. The ELISA experiments were done thrice with each cancer 
and HC. Total sample size (n=149); various cancer (n= 99) and as a 
control normal sera (n=50). The different between groups (patient 
versus control) were calculated to have significance at p value 0.05 
Distribution of anti-HABPs autoantibodies 
To evaluate the specificity and sensitivity we employed ELISA. The 
titers for anti-HABPs autoantibody  in  sera  of  Patients  with  cancer  
have significant higher circulating levels of anti-HABPs antibodies as 
compared to control subjects (� < 0.001).ROC plot test has exhibited 
91.9% sensitivity and 76.3% specificity (Fig.1). We also examined 
whether the level of anti-HABPs autoantibodies were detectable as a 
function of tumor types. The titers of anti-HABPs autoantibodies 
detected into patients with different cancer in comparison to the HC 
are depicted (Fig.2) In HC the mean ±SEM level was (0.25 ± 0.03) 
among cancer patients were mean ±SEM (0.99 ± 0.14, p value 0.001) 
for breast, mean ±SEM (0.97 ± 0.13. p value 0.015) for cervix, mean 
±SEM (1.0 ± 0.11, p value 0.035) for colon, mean ±SEM (0.80 ± 0.0.4) 
for ovarian, mean ±SEM (0.90 ± 0.05, p value 0.041) for stomach, 
mean ±SEM (1.4 ± 0.38) for rectum, mean ±SEM (0.91 ± 0.08, p value 
0.001) for lung cancer.  
 
*** (0.001, ** 0.01) 
Fig.3 
Figure.3 Dot plot showing levels of anti-HABPs autoantibodies as 
detected by ELISA, in patients with breast, cervix, colon, ovarian, 
stomach, rectum, lung, and HC. Each dot represents the datum for an 
individual subject. The solid and dotted horizontal lines indicate the 
mean level.  
The sensitivity and specificity of the anti-HABPs autoantibody 
detected by ELISA was evaluated using ROC plots, exhibited high 
sensitivity with 91.9% (95% confidence interval) and also 
maintaining high specificity of 76.3% (95% confidence interval) in 
discriminating between patient with cancer and HC and area under 
curve (AUC) was 0.85. So, this study clearly demonstrates the 
specificity of AAbs to HABPs in cancer (Fig.5). 
 
Fig.4 
Figure.4 ROC plots of HABPs autoantibody by EIA in patients with 
cancer and healthy control sera. The sensitivity and specificity of 
anti- HABPs autoantibody EIA (from the data of Fig. 1) was 
presented. The autoantibody EIA had a sensitivity of 91.9% and 
specificity of 76.3% (AUC, 0.85). 
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Figure. 5 immune blotting of anti-HABPs autoantibody in sera from 
patients with cancer and HC. Lane 1, molecular weight marker; lane 
2, breast cancer, Lane 3, cervix cancer (1:100 fold dilution); lane 4, 
blotted with bHA, lane 5 & 6, blotted with HC sera (1:100-fold 
dilution); lane 7,mAb cdc37 antibody and lane 8, mAb CD44 
antibody (HCAM). 
Immune blot analysis of anti-HABPs autoantibodies 
We also examined the immunologic identification of anti-HABPs 
autoantibodies present in the cancer sera and in HC. selected same 
patient sera exhibited immune reactivity towards purified HABPs 
and this result was correspond to bHA as multiple bands (120 kD, 80 
kD,57 kD,40 kD and 37 kD), whereas there was no such significant 
immune reactivity in HC.(Fig.6). In order to say that, autoantibodies 
could also have high affinity to known HA receptors we used mAb 
CD44 and mAb cdc37 as a control, this result was compare with 
(lane 2-4).  
DISCUSSION 
Numerous studies have demonstrated that cancer detection and 
diagnosis is a serious step in cancer management. Therefore, we 
vigorously validated the method and carefully evaluated the data. 
We measured elevated level of circulatory autoantibodies which is 
generated against HABPs. Circulatory serum autoantibodies 
recognize relevant HABPs in patients with cancer, suggesting that 
autoantibody-based tests may be used to differentiate patient with 
cancer from inflammation and HC [19]. Immunoblot analysis 
identified 120 kD, 80 kD, 57 kD, 47 kD and 37 kD as major HABPs 
and their relevant autoantibodies in patient with cancer and these 
proteins are directly associated with bioactive fragments or polymer 
HA and are involved in cell proliferation, cell-cell adhesion, 
differentiation and migration during tumorogenesis [20], and also 
these multiple HABPs (Hyaladherins) are known to be directly 
associated with metastasis and reported to play a vital role in 
carcinogenesis [14]. The over expression of HABPs were observed 
during tumorigesis but, not in HC. Hence HABPs could act as a 
protein biomarker and might provide important diagnostic 
information in cancer detection. The consistent results have been 
observed in cancer of breast, cervix in which the autoantibodies 
have been associated with cancer progression. In this study, we have 
used a simple ELISA technique, which allow the identification of 
autoantibodies and their corresponding tumor associated antigen 
(HABPs) and showed the elevated levels of autoantibodies directed 
against HABPs in the sera of patients with cancer but not 
significantly in the HC. 
Beside these, many of the well-known available tumor-associated 
serum biomarkers was studied, such as CEA for colon cancer, AFP 
for liver cancer, PSA for prostate cancer, CA19-9 for gastrointestinal 
cancer and CA-125 for ovarian cancer, [21]. Cancer testes (CT) 
antigens [22] Elevated serum protein level of any one of the above 
markers is less than 36% and combination of these markers range 
from 20-70% [19]. As such, the clinical application of these 
biomarkers is limited when assayed independently, although using 
combinations of markers have somewhat enhanced diagnostic value. 
Similarly, an antibody response to a single protein is not expected to 
be universal biomarker [23]. In spite of that, few of these biomarkers 
are acceptable for routine clinical applications. Owing to conflicting 
results from different studies showing low sensitivity and specificity 
[24,25]. Therefore, it is essential to identify clinical reliable 
biomarkers for tumor to develop an effective approach for early 
diagnosis. Finally, these markers are mostly used in conjunction 
with diagnostic imaging and physical examination to establish the 
initial diagnosis, to subsequently assess the efficacy of treatment and 
to monitor evidence of relapse. Therefore, it is of high clinical 
importance to develop an easy-to-perform screening test that can 
identify patients with cancer in early curable stages.  
In the present investigation, anti-HABPs autoantibodies were 
elevated with tumor progression. This elevation indicates that the 
serum AAbs against HABPs might represent cellular status. These 
results suggest that detection of circulating AAbs against HABPs 
could potentially serve as a useful serum biomarker for detecting 
cancer. Detection of anti-HABPs AAbs by immunoblot may be of 
limited value for routine use in most diagnostic laboratory. We used 
a simple and rapid ELISA method. The assays were used to measure 
these biomarkers need to have high sensitivity and specificity, anti-
HABPs AAbs were elevated in all malignantly transformed cells 
irrespective of cancers [26]. To our knowledge, no investigations 
have been reported on the autoantibodies against HABPs in the 
serum of patients with cancer. It has been established that anti-
HABPs autoantibodies are useful serological biomarkers in 
monitoring and diagnosis of cancer.  
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